Pfizer (PFE) said its Phase 2 study of tilrekimig (PF-07275315), a trispecific antibody for atopic dermatitis, showed positive results. The study met its primary endpoint, with tilrekimig showing a ...

A 15-day course of Pfizer's COVID-19 antiviral treatment Paxlovid did not relieve symptoms of long COVID, according to a study by Stanford University researchers. Currently, there are no proven ...

March 9 (Reuters) - U.S. drugmaker Pfizer said on Monday its experimental drug for a chronic skin disease met the main goal ...

NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) today announced positive topline results from the Phase 3 AFFINE study (NCT04370054) evaluating giroctocogene fitelparvovec, an investigational gene ...

A Pfizer drug recently awarded accelerated FDA approval in colorectal cancer now has additional data showing it met key goals in its pivotal study, results that could support an application seeking ...

This real-world study, conducted between September and December 2024, also showed that the impact of symptoms on daily activities, including work and family responsibilities, was lower in recipients ...

A new preprint study suggests that Moderna’s COVID-19 vaccine may be significantly more effective against symptomatic disease from the delta variant compared to Pfizer-BioNTech’s vaccine, while the ...

Pfizer is playing catch-up in the crowded field of obesity medicines, but it hoped to compete with a daily pill alternative to currently available injectable GLP-1 products. Instead, Pfizer is ...

The Pfizer company logo is displayed as traders work on the floor of the New York Stock Exchange during morning trading on April 10, 2023 in New York City. This story was originally published on ...

Pfizer Inc. (NYSE: PFE) disclosed the death of a participant in a long-term open-label extension study of marstacimab in patients with hemophilia A or B. In October 2024, the FDA approved Pfizer’s ...